Exact Sciences named Mark Stenhouse as president of Cologuard, its noninvasive stool DNA-based test for early detection of colon cancer, the company announced recently.

“More than 85 million people are eligible to be screened with Cologuard, and Mark brings the experience and passion to help us reach further into this enormous population,” Exact Sciences Chairman and CEO Kevin Conroy said in a statement. “Mark’s track record launching and guiding a product to blockbuster status, and his experience within the field of gastrointestinal diseases, makes him the ideal leader to amplify our early success after launching Cologuard.”

According to a release, Stenhouse has nearly 30 years experience in the pharmaceutical industry, previously working his way up to vice president at Abbott Laboratories/AbbVie.

Stenhouse will begin his position Monday, April 2.